NEW YORK (GenomeWeb) – Cowen has initiated coverage on Horizon Discovery Group with an Outperform rating and a £2.90 ($3.73) price target.

In a research note, Cowen's Doug Schenkel noted that Horizon has "quickly evolved into an emerging leader in gene editing life science tools," especially in the wake of the company's July acquisition of Dharmacon from GE.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: paternal age associated with de novo mutations in children, and more.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.